{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:51:07Z","timestamp":1768456267263,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2023IR50"],"award-info":[{"award-number":["2023IR50"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2023CX02"],"award-info":[{"award-number":["2023CX02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00259-025-07300-4","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T02:04:40Z","timestamp":1745546680000},"page":"4399-4413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A visual whole-body tumor-burden classification based on PSMA PET\/CT to predict response to novel androgen receptor signaling inhibitors for metastatic hormone-sensitive prostate cancer patients"],"prefix":"10.1007","volume":"52","author":[{"given":"Xuhe","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojiang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peimin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2873-9416","authenticated-orcid":false,"given":"Jianhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"7300_CR1","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1001\/jamaoncol.2022.4319","volume":"8","author":"AK Bryant","year":"2022","unstructured":"Bryant AK, Lee KM, Alba PR, Murphy JD, Martinez ME, Natarajan L, et al. Association of prostate-Specific antigen screening rates with subsequent metastatic prostate Cancer incidence at US veterans health administration facilities. JAMA Oncol. 2022;8:1747\u201355.","journal-title":"JAMA Oncol"},{"key":"7300_CR2","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316.","journal-title":"Lancet"},{"key":"7300_CR3","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686\u2013700.","journal-title":"Lancet Oncol"},{"key":"7300_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, Castration-Sensitive prostate Cancer. N Engl J Med. 2019;381:13\u201324.","journal-title":"N Engl J Med"},{"key":"7300_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard First-Line therapy in metastatic prostate Cancer. N Engl J Med. 2019;381:121\u201331.","journal-title":"N Engl J Med"},{"key":"7300_CR6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","volume":"24","author":"CJ Sweeney","year":"2023","unstructured":"Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:323\u201334.","journal-title":"Lancet Oncol"},{"key":"7300_CR7","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic Hormone-Sensitive prostate Cancer. J Clin Oncol. 2019;37:2974\u201386.","journal-title":"J Clin Oncol"},{"key":"7300_CR8","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved survival with enzalutamide in patients with metastatic Hormone-Sensitive prostate Cancer. J Clin Oncol. 2022;40:1616\u201322.","journal-title":"J Clin Oncol"},{"key":"7300_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.eururo.2023.04.002","volume":"84","author":"AJ Armstrong","year":"2023","unstructured":"Armstrong AJ, Iguchi T, Azad AA, Villers A, Alekseev B, Petrylak DP, et al. The efficacy of enzalutamide plus androgen deprivation therapy in oligometastatic Hormone-sensitive prostate cancer: A post hoc analysis of ARCHES. Eur Urol. 2023;84:229\u201341.","journal-title":"Eur Urol"},{"key":"7300_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/ijc.34018","volume":"151","author":"ND James","year":"2022","unstructured":"James ND, Clarke NW, Cook A, Ali A, Hoyle AP, Attard G, et al. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int J Cancer. 2022;151:422\u201334.","journal-title":"Int J Cancer"},{"key":"7300_CR11","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81\u20135.","journal-title":"Clin Cancer Res"},{"key":"7300_CR12","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.2967\/jnumed.122.265242","volume":"64","author":"M Hotta","year":"2023","unstructured":"Hotta M, Gafita A, Murthy V, Benz MR, Sonni I, Burger IA, et al. PSMA PET Tumor-to-Salivary gland ratio to predict response to [177Lu]PSMA radioligand therapy: an international multicenter retrospective study. J Nucl Med. 2023;64:1024\u20139.","journal-title":"J Nucl Med"},{"key":"7300_CR13","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00345-018-2403-7","volume":"37","author":"NJ Sathianathen","year":"2019","unstructured":"Sathianathen NJ, Butaney M, Konety BR. The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis. World J Urol. 2019;37:1239\u201349.","journal-title":"World J Urol"},{"key":"7300_CR14","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2967\/jnumed.121.262398","volume":"63","author":"I Sonni","year":"2022","unstructured":"Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach M, et al. Head-to-Head comparison of 68Ga-PSMA-11 PET\/CT and MpMRI with a histopathology gold standard in the detection, intraprostatic localization, and determination of local extension of primary prostate cancer: results from a prospective Single-Center imaging trial. J Nucl Med. 2022;63:847\u201354.","journal-title":"J Nucl Med"},{"key":"7300_CR15","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1007\/s00259-018-4255-1","volume":"46","author":"J Zhang","year":"2019","unstructured":"Zhang J, Shao S, Wu P, Liu D, Yang B, Han D, et al. Diagnostic performance of 68Ga-PSMA PET\/CT in the detection of prostate cancer prior to initial biopsy: comparison with cancer-predicting nomograms. Eur J Nucl Med Mol Imaging. 2019;46:908\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7300_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2214\/AJR.20.23912","volume":"216","author":"S Satapathy","year":"2021","unstructured":"Satapathy S, Singh H, Kumar R, Mittal BR. Diagnostic accuracy of 68Ga-PSMA PET\/CT for initial detection in patients with suspected prostate cancer: A systematic review and Meta-Analysis. AJR Am J Roentgenol. 2021;216:599\u2013607.","journal-title":"AJR Am J Roentgenol"},{"key":"7300_CR17","doi-asserted-by":"publisher","first-page":"786","DOI":"10.2967\/jnumed.118.219501","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate Cancer validated by histopathology. J Nucl Med. 2019;60:786\u201393.","journal-title":"J Nucl Med"},{"key":"7300_CR18","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s12094-024-03625-y","volume":"27","author":"I Henriquez","year":"2025","unstructured":"Henriquez I, Malave B, Campos FL, Hidalgo EC, Muelas R, Ferrer C, et al. PSMA PET\/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC). Clin Transl Oncol. 2025;27:706\u201315.","journal-title":"Clin Transl Oncol"},{"key":"7300_CR19","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic Hormone-Sensitive prostate cancer: Long-Term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36:1080\u20137.","journal-title":"J Clin Oncol"},{"key":"7300_CR20","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, Castration-Sensitive prostate Cancer. N Engl J Med. 2017;377:352\u201360.","journal-title":"N Engl J Med"},{"key":"7300_CR21","doi-asserted-by":"publisher","first-page":"1030187","DOI":"10.3389\/fonc.2022.1030187","volume":"12","author":"Y Ren","year":"2022","unstructured":"Ren Y, Liu C, Liu T, Duan X, Zhang Q, Liu J, et al. Preclinical evaluation and first in human study of Al18F radiolabeled ODAP-urea-based PSMA targeting ligand for PET imaging of prostate cancer. Front Oncol. 2022;12:1030187.","journal-title":"Front Oncol"},{"key":"7300_CR22","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/snmmi procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7300_CR23","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2967\/jnumed.118.224055","volume":"60","author":"A Gafita","year":"2019","unstructured":"Gafita A, Bieth M, Kronke M, Tetteh G, Navarro F, Wang H, et al. qPSMA: semiautomatic software for Whole-Body tumor burden assessment in prostate Cancer using 68Ga-PSMA11 PET\/CT. J Nucl Med. 2019;60:1277\u201383.","journal-title":"J Nucl Med"},{"key":"7300_CR24","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.2967\/jnumed.121.262120","volume":"62","author":"F Barbato","year":"2021","unstructured":"Barbato F, Fendler WP, Rauscher I, Herrmann K, Wetter A, Ferdinandus J, et al. PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease. J Nucl Med. 2021;62:1747\u201350.","journal-title":"J Nucl Med"},{"key":"7300_CR25","doi-asserted-by":"publisher","first-page":"810011","DOI":"10.3389\/fgene.2021.810011","volume":"12","author":"X Liao","year":"2021","unstructured":"Liao X, Liu M, Wang R, Zhang J. Potentials of Non-Invasive18F-FDG PET\/CT in immunotherapy prediction for Non-Small cell lung Cancer. Front Genet. 2021;12:810011.","journal-title":"Front Genet"},{"key":"7300_CR26","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1097\/MNM.0000000000001274","volume":"41","author":"X Liao","year":"2020","unstructured":"Liao X, Cui Y, Chen X, Di L, Tong Z, Liu M, et al. Primary metabolic tumor volume from 18F-FDG PET\/CT associated with epidermal growth factor receptor mutation in lung adenocarcinoma patients. Nucl Med Commun. 2020;41:1210\u20137.","journal-title":"Nucl Med Commun"},{"key":"7300_CR27","doi-asserted-by":"publisher","first-page":"e390166","DOI":"10.1200\/EDBK_390166","volume":"43","author":"AA Hamid","year":"2023","unstructured":"Hamid AA, Sayegh N, Tombal B, Hussain M, Sweeney CJ, Graff JN, et al. Metastatic Hormone-Sensitive prostate cancer: toward an era of adaptive and personalized treatment. Am Soc Clin Oncol Educ Book. 2023;43:e390166.","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07300-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07300-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07300-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T08:36:26Z","timestamp":1759394186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07300-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7300"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07300-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The study was approved by the Medical Ethics Committee of Peking University First Hospital (2023-510-002) and registered at chictr.org.cn (ChiCTR2100049791). Patients signed informed consent regarding publishing their data and photographs.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The requirement for informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}